Author

Julian Egger

Oregon Health & Science UniversityORCID 0000-0001-8418-0069Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Allison CreasoniD· 2 shared Christopher L. CorlessiD· 2 shared Koei ChiniD· 2 shared Lisa M. CoussensiD· 2 shared Shamilene SivagnanamiD· 2 shared Adel KardoshiD· 1 shared Alexander SmithiD· 1 shared Andrew AdeyiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Allison CreasonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintDec 15, 2025

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

Motoyuki Tsuda, Dove J. Keith, Colin J. Daniel…·Rosalie C. Sears

The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.

DOI 10.64898/2025.12.12.693851

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 27, 2023

Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers

Allison Creason, Julian Egger, Cameron Watson…·Jeremy Goecks

This study creates a multimodal tumor atlas to analyze how metastatic HR+ breast cancers adapt to CDK4/6 inhibitors, revealing mechanisms like mTORC1 activation and immune microenvironment changes.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky